Strategies blocking the interaction between programmed cell death protein 1 (PD-1) and PD ligand (PD-L)1/2, or between cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and CD80/CD86 have been developed to overcome the immune checkpoints in tumor tissue. This evidence concerns the gene PDCD1 and neoplasm.